DOCSLIB.ORG

Prior Authorization Protocol BELSOMRA® (Suvorexant)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prior Authorization Protocol BELSOMRA® (Suvorexant) Prior Authorization Protocol BELSOMRA (suvorexant), EDLUAR , INTERMEZZO (zolpidem sublingual tablets), ROZEREM (ramelteon), SILENOR® (doxepin), ZOLPIMIST ® (zolpidem spray) NATL Coverage of drugs is first determined by the member’s pharmacy benefit. Please consult with or refer to the Evidence of Coverage document. I. FDA Approved Indications: Edluar • Short-term treatment of insomnia characterized by difficulties with sleep initiation Intermezzo • Treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep Zolpimist • Short-term treatment of insomnia characterized by difficulties with sleep initiation. Rozerem • Treatment of insomnia characterized by difficulty with sleep onset Silenor • Treatment of insomnia characterized by difficulties with sleep maintenance Belsomra • Treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance II. Health Net Approved Indications and Usage Guidelines: Belsomra, Silenor • Diagnosis of insomnia AND • Failure or clinically significant adverse effects to zolpidem or zolpidem CR Intermezzo • Diagnosis of insomnia AND • History of insomnia with difficulty returning to sleep after middle of the night awakening Edluar, Zolpimist • Diagnosis of insomnia Confidential and Proprietary Page 1 Date Prepared: 11.23.05JE Approved by Health Net Pharmacy & Therapeutic s Committee: 02.14.06, 04.11.06, 05.16.07, 11.19.08, 11.18.09, 11.17.10, 11.9.11, 11.14.12, 11.20.13, 11.19.14, 11.18.15 Updated: 05.09.06 JE, 10.03.06 RG, 02.08.07CM, 06.13.07 JE, 06.21.07 JE, 01.31.08 A.Myong, MJMcClusky 02.02.08, 08.06.08 A Myong, 06.09.09 A Myong, 6.1.10 A Myong, 6.27.11 PWhite, 2.9.12 S Redline, 3.13.12 S Redline, 3.28.12 S Redline, 5.23.12 S Redline, 6.11.12 S Redline, 6.18.12 S Redline, 4.2.13 S Redline, 6.12.13 A Giordano, 6.20.14 S Ara, 07.22.14 S Ara, 09.09.14 JKawamata, 6.1.15 A Myong, 01.08.16 S Mirando, 06.14.16 S Tabarangao Prior Authorization Protocol BELSOMRA (suvorexant), EDLUAR , INTERMEZZO (zolpidem sublingual tablets), ROZEREM (ramelteon), SILENOR® (doxepin), ZOLPIMIST ® (zolpidem spray) NATL AND • Trial of zolpidem unless contraindicated Rozerem • Diagnosis of insomnia AND • Failure or clinically significant adverse effects to zolpidem OR • Patient has a previous history of substance abuse III. Coverage is Not Authorized For: • Non-FDA approved indications, which are not listed in the Health Net Approved Indications and Usage Guidelines section, unless there is sufficient documentation of efficacy and safety in the published literature IV. General Information: • Because sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. • Rozerem is a melatonin receptor agonist, Silenor is a histamine H1 receptor antagonist and Belsomra is an orexin receptor antagonist. These three agents do not work through the GABA-A receptors, as do the other available agents in this class. • Silenor is not a scheduled controlled substance. • Zolpidem has a Micromedex Class IIa indication for improving sleep in patients with SSRI- induced insomnia. The insomnia had been ongoing for two weeks while on the SSRI. • The recommended initial doses for women and men are different because zolpidem clearance is lower in women. V. Therapeutic Alternatives: Drug Dosing Regimen Dose/Limit/Maximum Dose flurazepam Adults: 15 - 30 mg PO QHS 30 mg/day (Dalmane ) Elderly**: 15 mg PO QHS **Generally not recommended in the elderly due to long half-life of active metabolite temazepam Adults: 15 - 30 mg PO QHS 30 mg/day (Restoril ) Elderly: 7.5 - 15 mg PO QHS Confidential and Proprietary Page 2 Date Prepared: 11.23.05JE Approved by Health Net Pharmacy & Therapeutic s Committee: 02.14.06, 04.11.06, 05.16.07, 11.19.08, 11.18.09, 11.17.10, 11.9.11, 11.14.12, 11.20.13, 11.19.14, 11.18.15 Updated: 05.09.06 JE, 10.03.06 RG, 02.08.07CM, 06.13.07 JE, 06.21.07 JE, 01.31.08 A.Myong, MJMcClusky 02.02.08, 08.06.08 A Myong, 06.09.09 A Myong, 6.1.10 A Myong, 6.27.11 PWhite, 2.9.12 S Redline, 3.13.12 S Redline, 3.28.12 S Redline, 5.23.12 S Redline, 6.11.12 S Redline, 6.18.12 S Redline, 4.2.13 S Redline, 6.12.13 A Giordano, 6.20.14 S Ara, 07.22.14 S Ara, 09.09.14 JKawamata, 6.1.15 A Myong, 01.08.16 S Mirando, 06.14.16 S Tabarangao Prior Authorization Protocol BELSOMRA (suvorexant), EDLUAR , INTERMEZZO (zolpidem sublingual tablets), ROZEREM (ramelteon), SILENOR® (doxepin), ZOLPIMIST ® (zolpidem spray) NATL Drug Dosing Regimen Dose/Limit/Maximum Dose triazolam Adults: 0.125 - 0.5 mg PO QHS Adults: 0.5 mg/day (Halcion ) Elderly: 0.125 - 0.25 mg PO QHS Elderly: 0.25 mg/day trazodone Adults: 50 - 100 mg PO QHS Up to 600 mg/day for depression. (Desyrel ) Elderly: 25 - 100 mg PO QHS Lower doses are used for insomnia. zolpidem Adults: 5-10 mg PO QHS 10 mg/day (Ambien ) Elderly: 5 mg PO QHS zaleplon Adults: 10 mg PO QHS Adults: 20 mg/day (Sonata ) Elderly: 5 mg PO QHS Elderly: 10 mg/day zolpidem Adults: 6.25-12.5 mg PO QHS 12.5 mg/day extended release Elderly: 6.25 mg PO QHS (Ambien CR ) *Requires Prior Authorization VI. Recommended Dosing Regimen and Authorization Limit: Drug Dosing Regimen Authorization Limit Edluar Women: 5 mg SL QHS NAT: Length of Benefit Men: 5 or 10 mg SL QHS Elderly: 5 mg SL QHS HNCA: Length of Benefit Intermezzo Women: 1.75 mg SL QD PRN Men: 3.5 mg SL QD PRN HNMC: Length of Benefit Elderly: 1.75 mg SL QD PRN Belsomra 10 mg PO QHS If the 10 mg dose is well-tolerated but not effective, the dose can be increased, not to exceed 20 mg once daily. Zolpimist Women: 5 mg PO QHS immediately before bedtime Men: 5-10 mg PO QHS immediately before bedtime Elderly: 5 mg PO QHS immediately before bedtime Rozerem for AHCS requests: Rozerem Adults: 8 mg PO QHS One Year Silenor Adults: 6 mg PO QHS (max 6 mg) Elderly: 3 mg PO QHS Confidential and Proprietary Page 3 Date Prepared: 11.23.05JE Approved by Health Net Pharmacy & Therapeutic s Committee: 02.14.06, 04.11.06, 05.16.07, 11.19.08, 11.18.09, 11.17.10, 11.9.11, 11.14.12, 11.20.13, 11.19.14, 11.18.15 Updated: 05.09.06 JE, 10.03.06 RG, 02.08.07CM, 06.13.07 JE, 06.21.07 JE, 01.31.08 A.Myong, MJMcClusky 02.02.08, 08.06.08 A Myong, 06.09.09 A Myong, 6.1.10 A Myong, 6.27.11 PWhite, 2.9.12 S Redline, 3.13.12 S Redline, 3.28.12 S Redline, 5.23.12 S Redline, 6.11.12 S Redline, 6.18.12 S Redline, 4.2.13 S Redline, 6.12.13 A Giordano, 6.20.14 S Ara, 07.22.14 S Ara, 09.09.14 JKawamata, 6.1.15 A Myong, 01.08.16 S Mirando, 06.14.16 S Tabarangao Prior Authorization Protocol BELSOMRA (suvorexant), EDLUAR , INTERMEZZO (zolpidem sublingual tablets), ROZEREM (ramelteon), SILENOR® (doxepin), ZOLPIMIST ® (zolpidem spray) NATL VII. Product Availability: Edluar sublingual tablets (not scored): 5 mg, 10 mg Intermezzo sublingual tablets: 1.75 mg, 3.5 mg Zolpimist oral spray: 5 mg per actuation Rozerem tablets: 8 mg Silenor tablets (not scored): 3 mg, 6 mg Belsomra tablets: 5 mg, 10 mg, 15 mg, 20 mg VIII. References: 1. Edluar [Prescribing Information] Somerset, NJ: Meda Pharmaceuticals, Inc.; October 2014. 2. Zolpimist [Prescribing Information] Richmond, VA:ECR Pharmaceuticals. May 2013. 3. Rozerem [Prescribing Information] Deerfield, IL: Takeda Pharmaceuticals America Inc. November 2010. 4. Intermezzo [Prescribing Information] Stamford, CT: Purdue Pharma L.P. July 2015 5. Silenor [Prescribing Information] Morristown, NJ: Pernix Therapeutics, LLC, Inc. March 2010. 6. Belsomra [Prescribing Information} Whitehouse Station, NJ: Merck & Co, Inc.; May 2016. 7. Micromedex ® Healthcare Series (Internet Database). Greenwood Village, CO: Thompson Healthcare. Updated periodically. Accessed July 2016 The materials provided to you are guidelines used by this health plan to authorize, modify, or determine coverage for persons with similar illnesses or conditions. Specific care and treatment may vary depending on individual needs and the benefits covered under your contract. Confidential and Proprietary Page 4 Date Prepared: 11.23.05JE Approved by Health Net Pharmacy & Therapeutic s Committee: 02.14.06, 04.11.06, 05.16.07, 11.19.08, 11.18.09, 11.17.10, 11.9.11, 11.14.12, 11.20.13, 11.19.14, 11.18.15 Updated: 05.09.06 JE, 10.03.06 RG, 02.08.07CM, 06.13.07 JE, 06.21.07 JE, 01.31.08 A.Myong, MJMcClusky 02.02.08, 08.06.08 A Myong, 06.09.09 A Myong, 6.1.10 A Myong, 6.27.11 PWhite, 2.9.12 S Redline, 3.13.12 S Redline, 3.28.12 S Redline, 5.23.12 S Redline, 6.11.12 S Redline, 6.18.12 S Redline, 4.2.13 S Redline, 6.12.13 A Giordano, 6.20.14 S Ara, 07.22.14 S Ara, 09.09.14 JKawamata, 6.1.15 A Myong, 01.08.16 S Mirando, 06.14.16 S Tabarangao .
Load more

Recommended publications
  • Journal of Pharmacology and Experimental Therapeutics
    Journal of Pharmacology and Experimental Therapeutics Molecular Determinants of Ligand Selectivity for the Human Multidrug And Toxin Extrusion Proteins, MATE1 and MATE-2K Bethzaida Astorga, Sean Ekins, Mark Morales and Stephen H Wright Department of Physiology, University of Arizona, Tucson, AZ 85724, USA (B.A., M.M., and S.H.W.) Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina NC 27526, USA (S.E.) Supplemental Table 1. Compounds selected by the common features pharmacophore after searching a database of 2690 FDA approved compounds (www.collaborativedrug.com). FitValue Common Name Indication 3.93897 PYRIMETHAMINE Antimalarial 3.3167 naloxone Antidote Naloxone Hydrochloride 3.27622 DEXMEDETOMIDINE Anxiolytic 3.2407 Chlordantoin Antifungal 3.1776 NALORPHINE Antidote Nalorphine Hydrochloride 3.15108 Perfosfamide Antineoplastic 3.11759 Cinchonidine Sulfate Antimalarial Cinchonidine 3.10352 Cinchonine Sulfate Antimalarial Cinchonine 3.07469 METHOHEXITAL Anesthetic 3.06799 PROGUANIL Antimalarial PROGUANIL HYDROCHLORIDE 100MG 3.05018 TOPIRAMATE Anticonvulsant 3.04366 MIDODRINE Antihypotensive Midodrine Hydrochloride 2.98558 Chlorbetamide Antiamebic 2.98463 TRIMETHOPRIM Antibiotic Antibacterial 2.98457 ZILEUTON Antiinflammatory 2.94205 AMINOMETRADINE Diuretic 2.89284 SCOPOLAMINE Antispasmodic ScopolamineHydrobromide 2.88791 ARTICAINE Anesthetic 2.84534 RITODRINE Tocolytic 2.82357 MITOBRONITOL Antineoplastic Mitolactol 2.81033 LORAZEPAM Anxiolytic 2.74943 ETHOHEXADIOL Insecticide 2.64902 METHOXAMINE Antihypotensive Methoxamine
    [Show full text]
  • Paper Clip—High Risk Medications
    You belong. PAPER CLIP—HIGH RISK MEDICATIONS Description: Some medications may be risky for people over 65 years of age and there may be safer drug choices to treat some conditions. It is recommended that medications are reviewed regularly with your providers/prescriber to ensure patient safety. Condition Treated Current Medication(s)-High Risk Safer Alternatives to Consider Urinary Tract Infections (UTIs), Nitrofurantoin Bactrim (sulfamethoxazole/trimethoprim) or recurrent UTIs, or Prophylaxis (Macrobid, or Macrodantin) Trimpex/Proloprim/Primsol (trimethoprim) Allergies Hydroxyzine (Vistaril, Atarax) Xyzal (Levocetirizine) Anxiety Hydroxyzine (Vistaril, Atarax) Buspar (Buspirone), Paxil (Paroxetine), Effexor (Venlafaxine) Parkinson’s Hydroxyzine (Vistaril, Atarax) Symmetrel (Amantadine), Sinemet (Carbidopa/levodopa), Selegiline (Eldepryl) Motion Sickness Hydroxyzine (Vistaril, Atarax) Antivert (Meclizine) Nausea & Vomiting Hydroxyzine (Vistaril, Atarax) Zofran (Ondansetron) Insomnia Hydroxyzine (Vistaril, Atarax) Ramelteon (Rozerem), Doxepin (Silenor) Chronic Insomnia Eszopiclone (Lunesta) Ramelteon (Rozerem), Doxepin (Silenor) Chronic Insomnia Zolpidem (Ambien) Ramelteon (Rozerem), Doxepin (Silenor) Chronic Insomnia Zaleplon (Sonata) Ramelteon (Rozerem), Doxepin (Silenor) Muscle Relaxants Cyclobenazprine (Flexeril, Amrix) NSAIDs (Ibuprofen, naproxen) or Hydrocodone Codeine Tramadol (Ultram) Baclofen (Lioresal) Tizanidine (Zanaflex) Migraine Prophylaxis Elavil (Amitriptyline) Propranolol (Inderal), Timolol (Blocadren), Topiramate (Topamax),
    [Show full text]
  • Insomnia in Adults
    New Guideline February 2017 The AASM has published a new clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults. These new recommendations are based on a systematic review of the literature on individual drugs commonly used to treat insomnia, and were developed using the GRADE methodology. The recommendations in this guideline define principles of practice that should meet the needs of most adult patients, when pharmacologic treatment of chronic insomnia is indicated. The clinical practice guideline is an essential update to the clinical guideline document: Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–349. SPECIAL ARTICLE Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults Sharon Schutte-Rodin, M.D.1; Lauren Broch, Ph.D.2; Daniel Buysse, M.D.3; Cynthia Dorsey, Ph.D.4; Michael Sateia, M.D.5 1Penn Sleep Centers, Philadelphia, PA; 2Good Samaritan Hospital, Suffern, NY; 3UPMC Sleep Medicine Center, Pittsburgh, PA; 4SleepHealth Centers, Bedford, MA; 5Dartmouth-Hitchcock Medical Center, Lebanon, NH Insomnia is the most prevalent sleep disorder in the general popula- and disease management of chronic adult insomnia, using existing tion, and is commonly encountered in medical practices. Insomnia is evidence-based insomnia practice parameters where available, and defined as the subjective perception of difficulty with sleep initiation, consensus-based recommendations to bridge areas where such pa- duration, consolidation, or quality that occurs despite adequate oppor- rameters do not exist.
    [Show full text]
  • Nonbenzodiazepine Sedatives
    24. Haller C, Thai D, Jacob P, Dyer JE: GHB urine concentrations after single-dose adminis- CHAPTER Nonbenzodiazepine tration in humans. J Anal Toxicol 30: 360, 2006. [PMID: 16872565] 25. Wong CG, Gibson KM, Snead O: From the street to the brain: neurobiology of the rec- Sedatives reational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci 25: 29, 2004. [PMID: 184 14723976] Frank LoVecchio 26. White CM: Pharmacologic, pharmacokinetic, and clinical assessment of illicitly used γ-hydroxybutyrate. J Clin Pharmacol 57: 33, 2017. [PMID: 27198055] 27. Liakoni E, Walther F, Nickel CH, Liechti ME: Presentations to an urban emergency department in Switzerland due to acute γ-hydroxybutyrate toxicity. Scand J Trauma REFERENCES Resusc Emerg Med 24: 107, 2016. [PMID: 27581664] 28. Thai D, Dyer JE, Benowitz NL, Haller CA: Gamma-hydroxybutyrate and ethanol effects 1. Richey SM, Krystal AD: Pharmacological advances in the treatment of insomnia. Curr and interactions in humans. J Clin Psychopharm 26: 549, 2006. [PMID: 16974199] Pharm Des 17: 1471, 2011. [PMID: 21476952] 29. Miró Ò, Galicia M, Dargan P, et al: Intoxication by gamma hydroxybutyrate and related 2. http://www.digitalcitizensalliance.org/cac/alliance/content.aspx?page=Darknet. (Digital analogues: clinical characteristics and comparison between pure intoxication and that Citizens Alliance: Darknet Marketplace Watch: monitoring sales of illegal drugs on the combined with other substances of abuse. Toxicol Lett 277: 84, 2017. [PMID: 28579487] Darknet.) Accessed December 15, 2014. 30. Dietze P, Horyniak D, Agius P, et al: Effect of Intubation for gamma-hydroxybutyric acid 3. Loane C, Politis M: Buspirone: what is it all about? Brain Res 1461: 111, 2012.
    [Show full text]
  • Anxiety Disorders, Insomnia, PTSD, OCD
    2/3/2020 Anxiety Disorders, Insomnia, PTSD, OCD Steven L. Dubovsky, M.D. 1 2/3/2020 Basic Benzodiazepine Structure R1 R2 N C R7 C R3 C=N R4 R2′ Benzodiazepine R1 R2 R3 R7 R2′ Alprazolam Fused triazolo ring -H -Cl -H Chlordiazepoxide - -NHCH3 -H -Cl -H Clonazepam -H =O -H NO2 -Cl Diazepam -CH3 =O -H -Cl -H 2 2/3/2020 GABA-Benzodiazepine Receptor Complex GABA BZD Cl- 3 2/3/2020 Benzodiazepine Action GABA Cl- + + BZD - Cl- Inverse agonist Flumazenil • Benzodiazepine receptor antagonist R1 R2 • Therapeutic uses: C N – Benzodiazepine overdose R3 C R7 N C – Reversal of conscious sedation R4 = – Reversal of hepatic encephalopathy symptoms R2′ – Facilitation of benzodiazepine withdrawal • Can provoke withdrawal and induce anxiety 4 2/3/2020 BZD Receptor Subtypes • Type 1: Limbic system, locus coeruleus – Anxiolytic • Type 2: Cortex, pyramidal cells – Muscle relaxation, anticonvulsant, CNS depression, sedation, psychomotor impairment • Type 3: Mitochondria, periphery – Dependence, withdrawal BZD Features • Potency – High potency: Midazolam (Versed), alprazolam (Xanax), triazolam (Halcion) – Low potency: Chlordiazepoxide (Librium), flurazepam (Dalmane) • Lipid solubility – High solubility: Alprazolam, diazepam (Valium) – Low solubility: Lorazepam (Ativan), chlordiazepoxide (Librium) • Elimination half-life – Long half-life: Diazepam, chlordiazepoxide – Short half-life: Alprazolam, midazolam 5 2/3/2020 Potency • High potency – Smaller dose to produce same effect – More receptor occupancy – More intense withdrawal • Low potency – Higher doses used
    [Show full text]
  • Report on the Deliberation Results February 5, 2010 Evaluation And
    Report on the Deliberation Results February 5, 2010 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare [Brand name] Rozerem Tablets 8 mg [Non-proprietary name] Ramelteon (JAN*) [Applicant] Takeda Pharmaceutical Company Limited [Date of application] February 29, 2008 [Results of deliberation] In the meeting held on January 29, 2010, the First Committee on New Drugs concluded that the product may be approved and that this result should be presented to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The product is not classified as a biological product or a specified biological product, the re-examination period is 8 years, and the drug substance is classified as a powerful drug and the drug product is not classified as a poisonous drug or a powerful drug. *Japanese Accepted Name (modified INN) This English version of the Japanese review report is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. The PMDA will not be responsible for any consequence resulting from the use of this English version. Review Report January 15, 2010 Pharmaceuticals and Medical Devices Agency The results of a regulatory review conducted by the Pharmaceuticals and Medical Devices Agency on the following pharmaceutical product submitted for registration are as follows. [Brand name] Rozerem Tablets 8 mg [Non-proprietary name]
    [Show full text]
  • 1 RAMELTEON: a MELATONIN RECEPTOR AGONIST 2 Richard Wurtman, MD 3 Massachusetts Institute of Technology, Cambridge, MA, 02139
    1 RAMELTEON: A MELATONIN RECEPTOR AGONIST 2 Richard Wurtman, M.D. 3 Massachusetts Institute of Technology, Cambridge, MA, 02139, USA 4 5 6 7 8 9 10 11 12 13 14 Keywords: (Ramelteon), melatonin, pineal, MTI receptors, MT2 receptors, sleep, 15 GABA receptors, aging, desensitization 16 17 18 19 Address for correspondence: 77 Mass Ave. 46-5023 20 Cambridge, MA, 02139, USA 21 Telephone: 617-253-6731 22 FAX: 617-253-6882 23 e-mail: [email protected] ---------- 1 A. Summary: Ramelteon, the first melatonin receptor agonist to win FDA approval, 2 is presently marketed in the United States; its use is authorized to be marketed in the 3 United States for "..the treatment of insomnia associated with sleep onset". In laboratory 4 tests ramelteon has not exhibited potential for being abused or causing dependency, nor 5 has it been shown to interact with the neurotransmitter receptors that tend to be most 6 associated with these phenomena. Hence unlike other hypnotic agents ramelteon is a non- 7 scheduled drug. Few data have been published in peer-reviewedjournals describing 8 ramelteon's efficacy or side-effects in patients who actually suffer from insomnia, and no 9 comparison study has been performed to determine whether, when used at its 10 recommended 8 mg dose, ramelteon has any advantage over physiologic doses of 11 melatonin (0.2 - 0.5 mg), particularly for long-term use in older patients. 2 - - 1 2 B. Introduction 3 Ramelteon is the first FDA-approved agent believed to act by mimicking the 4 effects of the hormone melatonin.
    [Show full text]
  • Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: an American Academy of Sleep Medicine Clinical Practice Guideline Michael J
    pii: jc-00382-16 http://dx.doi.org/10.5664/jcsm.6470 SPECIAL ARTICLES Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline Michael J. Sateia, MD1; Daniel J. Buysse, MD2; Andrew D. Krystal, MD, MS3; David N. Neubauer, MD4; Jonathan L. Heald, MA5 1Geisel School of Medicine at Dartmouth, Hanover, NH; 2University of Pittsburgh School of Medicine, Pittsburgh, PA; 3University of California, San Francisco, San Francisco, CA; 4Johns Hopkins University School of Medicine, Baltimore, MD; 5American Academy of Sleep Medicine, Darien, IL Introduction: The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad classes of drugs, this guideline focuses on individual drugs commonly used to treat insomnia. It includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication for this condition. This guideline should be used in conjunction with other AASM guidelines on the evaluation and treatment of chronic insomnia in adults. Methods: The American Academy of Sleep Medicine commissioned a task force of four experts in sleep medicine. A systematic review was conducted to identify randomized controlled trials, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence. The task force developed recommendations and assigned strengths based on the quality of evidence, the balance of benefits and harms, and patient values and preferences.
    [Show full text]
  • A Comparative Study of Agomelatine and Ramelteon for Attenuation of Haemodynamic Response to Laryngoscopy and Endotracheal Intubation
    Original Article ISSN (0): 2456-7388; ISSN (P): 2617-5479 A Comparative study of Agomelatine and Ramelteon for Attenuation of Haemodynamic response to Laryngoscopy and Endotracheal Intubation Pradeep Hosagoudar 1, Arunashree S 2, M. Venkateswara Pradeep 3 1Professor, Department of Anaesthesiology, East Point College of Medical Sciences and Research, Bangalore, 2Senior Resident, Department of Anaesthesiology, Karwar Institute of Medical Sciences, Karwar, Karnataka., 3Senior Resident, Department of Anaesthesiology, P.E.S. Institute of Medical Sciences and Research, Kuppam, Andhra Pradesh. Abstract Background: Pressor response to laryngoscopy and endotracheal intubation is a well recognised clinical entity, and many medications have been used for its attenuation. Agomelatine and Ramelteon are analogues of Melatonin which have been recently used for preoperative anxiolysis and sedation with less known effects on pressor response. Subjects and Methods: 60 ASA-I patients scheduled for elective surgeries under general anaesthesia were randomly allocated into 2 equal groups. Group-A (Tab.agomelatine 10 mg) and Group-R (Tab.ramelteon 8mg) were administered per oral 1 hour prior to induction of anaesthesia. Heart rate and blood pressure were assessed preoperatively and at 0,1,3,5,10,15 minutes. Results: Reduction heart rate and blood pressure were noted when compared to baseline in both the groups(p<0.05). However there was no statistical difference between the two groups at various intervals of time and were comparable (p>0.05). Conclusion: Oral agomelatine and ramelteon when administered 1 hour prior to induction of anaesthesia, resulted in comparable reduction of heart rate and blood pressure response to laryngoscopy and endotracheal intubation. Keywords: laryngoscopy, endotracheal intubation, agomelatine, ramelteon.
    [Show full text]
  • ROZEREM Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Reproductive effects: Include decreased testosterone and increased These highlights do not include all the information needed to use prolactin levels. Effect on reproductive axis in developing humans is ROZEREM safely and effectively. See full prescribing information for unknown. (5.5) ROZEREM. • Patients with severe sleep apnea: ROZEREM is not recommended for use in this population. (5.6) ROZEREM (ramelteon) tablets, for oral use Initial U.S. Approval: 2005 --------------------------------ADVERSE REACTIONS------------------------------ Most common adverse reactions (≥3% and more common than with --------------------------INDICATIONS AND USAGE------------------------------- placebo) are: somnolence, dizziness, fatigue, nausea, and exacerbated ROZEREM is indicated for the treatment of insomnia characterized by insomnia. (6.1) difficulty with sleep onset. (1) To report SUSPECTED ADVERSE REACTIONS, contact Takeda -----------------------DOSAGE AND ADMINISTRATION------------------------ Pharmaceuticals at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1- • Adult dose: 8 mg taken within 30 minutes of going to bed. (2.1) 800-FDA-1088 or www.fda.gov/medwatch. • Should not be taken with or immediately after a high-fat meal. (2.1) • Total daily dose should not exceed 8 mg. (2.1) --------------------------------DRUG INTERACTIONS-------------------------------- • Rifampin (strong CYP enzyme inducer): Decreases exposure to and ----------------------DOSAGE FORMS AND STRENGTHS---------------------- effects of ramelteon.
    [Show full text]
  • Therapeutic Class Overview Sedative Hypnotics
    Therapeutic Class Overview Sedative Hypnotics Therapeutic Class • Overview/Summary: Insomnia is the most common sleep disorder in adulthood, affecting 33 to 69% of the population. It is estimated that five to ten percent of adults experience specific insomnia disorders.1,2 Insomnia is a disorder that results from a difficulty in initiating or maintaining sleep, waking too early, or sleep that is considered nonrestorative or poor quality.1-3 Furthermore, individuals with insomnia must also report at least one of the following types of daytime impairment as a result of the difficulties experienced with sleep: fatigue/malaise; impairment in memory, attention, or concentration; social or work-related dysfunction; poor school performance; irritability; day time sleepiness; loss of motivation, energy, or initiative; increased tendency for work or driving related accidents/errors; tension headaches; gastrointestinal symptoms; or concerns/worries about sleep. In individuals with insomnia, these complaints occur despite having sufficient opportunity and circumstances for sleep.1,2 According to the International Classification of Sleep Disorders, insomnia may be classified as one of the following: short-term insomnia, chronic insomnia or other insomnia (defined as patients who experience difficulty initiating or maintaining sleep but do not meet all of the criteria for either short-term or chronic insomnia).2 There are several classes of medications available for the management of insomnia.4-6 Doxepin (Silenor®) is a tricyclic antidepressant that
    [Show full text]
  • Insomnia in Patients with Addictions: a Safer Way to Break the Cycle
    Insomnia in patients with addictions: A safer way to break the cycle Fight relapse by improving sleep with nonaddictive agents and behavior therapy ® Dowden Health Media rom alcohol to opioids, most addictive substances can induce sleep disturbances that persist despite Fabstinence and mayCopyright increase theFor risk forpersonal relapse. use only Nearly all FDA-approved hypnotics are Schedule IV controlled substances that—although safe and effective for most populations—are prone to abuse by patients with substance use disorders. You’re not alone if you hesitate to prescribe hypnot- BISSELL ics to these patients; a study of 311 addiction medicine physicians found that they prescribed sleep-promoting medication to only 30% of their alcohol-dependent pa- tients with insomnia.1 IMAGES/CHRISTOPHER This article presents evidence on how alcohol and GETTY other substances disturb sleep in patients with addic- 2008 © tions. We discuss the usefulness of hypnotics, off-label sedatives, and cognitive-behavioral therapy (CBT). Our Deirdre Conroy, PhD Clinical assistant professor of psychiatry goal is to help you reduce your patients’ risk of relapse by addressing their sleep complaints. J. Todd Arnedt, PhD Clinical assistant professor of psychiatry and neurology Kirk J. Brower, MD Workup: 3 principles Associate professor of psychiatry Insomnia is multifactorial. Don’t assume that sub- stance abuse is the only cause of prominent insomnia University of Michigan Ann Arbor complaints. Insomnia in patients with substance use dis- orders may be a manifestation of protracted withdrawal or a primary sleep disorder. Evaluate your patient’s: • other illnesses (psychiatric, medical, and other sleep disorders) • sleep-impairing medications (such as activating Current Psychiatry antidepressants and theophylline) Vol.
    [Show full text]